Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Piramal Pharma Limited ( (IN:PPLPHARMA) ).
Piramal Pharma Limited has announced that it will host an earnings conference call for investors and analysts on 29 January 2026 to discuss its financial results for the third quarter and nine months of FY2026. By formally scheduling this call and sharing access details for participants across multiple geographies, the company is underscoring its focus on transparent communication with capital markets, and the discussion is likely to provide stakeholders with updates on operational performance across its contract development, hospital generics, consumer healthcare and strategic investment portfolios.
More about Piramal Pharma Limited
Piramal Pharma Limited is a diversified pharmaceutical company operating through 17 global development and manufacturing facilities and a distribution network spanning over 100 countries. Its businesses include Piramal Pharma Solutions, an integrated contract development and manufacturing organization; Piramal Critical Care, focused on complex hospital generics; and Piramal Consumer Healthcare, which sells over-the-counter consumer and wellness products. The company also has an associate joint venture, Abbvie Therapeutics India, which is a leading player in ophthalmology in the Indian market, and holds a strategic minority stake in Yapan Bio, active in biologics, biotherapeutics and vaccines.
Average Trading Volume: 233,446
Technical Sentiment Signal: Sell
Current Market Cap: 223.4B INR
For detailed information about PPLPHARMA stock, go to TipRanks’ Stock Analysis page.